ArQule's (ARQL) tivantinib (ARQ 197) did not meet its primary endpoint in Phase 2 testing, says...

|By:, SA News Editor

ArQule's (ARQL) tivantinib (ARQ 197) did not meet its primary endpoint in Phase 2 testing, says the company. Shares remain halted.